CRIS Current Research Information System

GUGLIOTTA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.590
EU - Europa 3.121
AS - Asia 1.761
AF - Africa 227
SA - Sud America 16
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.584
GB - Regno Unito 1.129
CN - Cina 690
SG - Singapore 480
SE - Svezia 471
IT - Italia 412
DE - Germania 391
VN - Vietnam 287
IN - India 183
IE - Irlanda 140
FR - Francia 119
RU - Federazione Russa 119
UA - Ucraina 102
TG - Togo 83
ZA - Sudafrica 77
EE - Estonia 72
BG - Bulgaria 51
JO - Giordania 47
NG - Nigeria 38
CH - Svizzera 35
BE - Belgio 22
CI - Costa d'Avorio 19
FI - Finlandia 19
JP - Giappone 15
ID - Indonesia 12
AU - Australia 8
IR - Iran 8
TW - Taiwan 8
SC - Seychelles 7
BR - Brasile 6
CA - Canada 6
CL - Cile 6
NL - Olanda 6
AT - Austria 5
GR - Grecia 5
CZ - Repubblica Ceca 4
HK - Hong Kong 4
IL - Israele 4
IQ - Iraq 4
KR - Corea 4
LB - Libano 4
NO - Norvegia 4
PL - Polonia 4
TR - Turchia 4
EC - Ecuador 3
DK - Danimarca 2
LT - Lituania 2
PT - Portogallo 2
RO - Romania 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BD - Bangladesh 1
BO - Bolivia 1
EG - Egitto 1
EU - Europa 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RS - Serbia 1
Totale 9.725
Salva come PNG Salva come JPEG
Città #
Southend 1.072
Fairfield 606
Chandler 484
Singapore 443
Ashburn 374
Woodbridge 298
Wilmington 294
Houston 283
Seattle 270
Dong Ket 226
Cambridge 220
Princeton 203
Ann Arbor 170
Dublin 140
Boardman 127
Beijing 115
Nanjing 100
Santa Clara 96
Bologna 92
Lomé 83
Westminster 83
Padova 71
Berlin 65
Sofia 51
Jinan 48
Amman 47
Shenyang 42
New York 41
Abeokuta 38
Jacksonville 38
Turin 35
Changsha 34
Saint Petersburg 33
Bern 30
Nanchang 27
San Diego 27
Tianjin 27
Medford 25
Falls Church 24
Redmond 24
Jiaxing 23
Brussels 22
Hebei 21
Milan 21
Bremen 20
Abidjan 19
Mountain View 19
Helsinki 18
Des Moines 17
Norwalk 17
Zhengzhou 16
Dearborn 15
Shanghai 15
Rome 14
Chengdu 12
Guangzhou 12
Haikou 12
Hangzhou 12
Los Angeles 11
Redwood City 11
Taizhou 11
Jakarta 10
Ningbo 10
Frankfurt am Main 9
Kuban 9
Mülheim 9
Hyderabad 8
Olalla 8
Bühl 7
Florence 7
Paris 7
Mahé 6
Washington 6
Fuzhou 5
Harbin 5
London 5
São Paulo 5
Toronto 5
Wuhan 5
Boydton 4
Cernusco sul Naviglio 4
Chicago 4
Kunming 4
Lanzhou 4
Moscow 4
Phoenix 4
Warsaw 4
Andover 3
Brescia 3
Buffalo 3
Chongqing 3
Ferrara 3
Forlì 3
Foshan 3
Groningen 3
Las Vegas 3
Modena 3
Negrar 3
San Francisco 3
San Venanzo 3
Totale 7.041
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 333
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 205
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 198
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 165
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 164
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 161
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 158
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study 144
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 141
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 136
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 136
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 129
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 129
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 128
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 125
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 125
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 123
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 123
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 123
null 122
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 119
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 119
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 117
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 117
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 114
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 113
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 113
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 112
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 111
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 111
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 110
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 110
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 109
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 108
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 108
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 106
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 106
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 104
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 104
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 103
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 103
Diagnosis and classification of the risk 102
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 101
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 101
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 101
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 100
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 100
A review of the European LeukemiaNet recommendations for the management of CML 99
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 99
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 97
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 96
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 94
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 92
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 92
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 92
Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia 91
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 90
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 89
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML 88
Essential role of lyn in fibrosis 88
Safety profiles of first-line TKIS and managing adverse effects 87
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 86
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond 86
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 84
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 83
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 83
First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies 82
Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study 82
null 81
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 80
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 80
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase 80
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 80
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 79
null 77
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 76
null 76
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 75
EARLY PREDICTORS OF PROGRESSION TO ACCELERATED-BLASTIC PHASE IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 72
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 72
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 70
EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS 69
Imatinib in chronic myeloid leukemia elderly patients. 67
Thyrosin kinase inhibitors: nilotinib 66
null 66
Differences among young adults, adults and elderly chronic myeloid leukemia patients 60
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 58
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 52
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 52
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 51
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 49
Response definitions and European Leukemianet Management recommendations. 42
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 42
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 40
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 40
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools 38
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 37
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 36
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 35
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 34
Totale 9.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.973 0 0 0 0 291 237 328 318 347 183 102 167
2020/20211.385 230 103 36 44 30 41 26 108 153 60 150 404
2021/20221.674 153 57 137 140 170 99 27 97 83 103 286 322
2022/20232.011 203 310 108 247 160 141 87 125 347 36 161 86
2023/2024516 28 84 36 55 48 119 25 19 23 32 20 27
2024/20251.071 76 357 205 165 268 0 0 0 0 0 0 0
Totale 10.007